Dexcom's glucose monitor use shows benefit in non-insulin diabetic patients in study

By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to ...

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives ...

Dexcom study finds G7 glucose monitor improves blood sugar control in type 2 diabetes patients

A new study presented at the American Diabetes Association found that Dexcom’s G7 continuous glucose monitor significantly ...

DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?

DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line ...

Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative?

In May 2026, Dexcom disclosed FDA-enforced, Class II voluntary recalls of its G7 and ONE/ONE+ iOS and watchOS apps worldwide due to a software defect that can delay or replay glucose readings and ...
Business Wire

Dexcom G6 Real-Time CGM System Now Accessible to Any Eligible Client Managing Diabetes With Insulin Through NIHB

The Non-Insured Health Benefits (NIHB) program establishes exemplary coverage for Dexcom’s real-time continuous glucose monitoring system – bringing game-changing technology to more First Nations and ...
Nasdaq

Dexcom and Insulet Announce Commercial Agreement to Integrate the Dexcom G6 and Future G7 CGM into Insulet’s Omnipod Horizon™ Automated Insulin Delivery System

First-ever automated insulin delivery with the tubeless Omnipod Insulin Management System and personal smartphone control Initially compatible with Dexcom G6 CGM, with no fingersticks* required ...